

Sounak Gupta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/78321/publications.pdf>

Version: 2024-02-01

80
papers

1,651
citations

361045

20
h-index

329751

37
g-index

81
all docs

81
docs citations

81
times ranked

1942
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	7.7	179
2	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	2.9	138
3	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	2.9	118
4	Magnetic Resonance Elastography. <i>Mayo Clinic Proceedings</i> , 2015, 90, 882-894.	1.4	103
5	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	1.9	76
6	TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. <i>Modern Pathology</i> , 2017, 30, 998-1012.	2.9	70
7	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. <i>Clinical Cancer Research</i> , 2019, 25, 7113-7125.	3.2	69
8	Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. <i>Human Pathology</i> , 2019, 91, 114-122.	1.1	57
9	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. <i>Modern Pathology</i> , 2019, 32, 1344-1358.	2.9	49
10	TFEB Expression Profiling in Renal Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1445-1461.	2.1	38
11	Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics. <i>Human Pathology</i> , 2021, 114, 9-18.	1.1	37
12	Mammalian Target of Rapamycin Complex 2 (mTORC2) Is a Critical Determinant of Bladder Cancer Invasion. <i>PLoS ONE</i> , 2013, 8, e81081.	1.1	35
13	Outcome prediction for patients with renal cell carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 172-183.	1.0	35
14	Transforming Growth Factor- β 2 Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion. <i>American Journal of Pathology</i> , 2016, 186, 1351-1360.	1.9	33
15	Hepatocellular Neoplasms Arising in Association With Androgen Use. <i>American Journal of Surgical Pathology</i> , 2016, 40, 454-461.	2.1	32
16	Renal Neoplasia in Tuberous Sclerosis: A Study of 41 Patients. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1470-1489.	1.4	31
17	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.	3.2	30
18	High grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma. <i>Pathology</i> , 2015, 47, 533-542.	0.3	26

#	ARTICLE	IF	CITATIONS
19	Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. <i>European Urology</i> , 2021, 79, 225-231.	0.9	25
20	Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2 \pm Activity and Is Targetable by PEGylated Arginine Deiminase. <i>American Journal of Pathology</i> , 2017, 187, 200-213.	1.9	23
21	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	2.4	23
22	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	0.9	22
23	JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy. <i>Human Pathology</i> , 2019, 88, 87-91.	1.1	20
24	A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 253-263.	1.2	20
25	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	2.4	20
26	Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 307-317.	1.2	19
27	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. <i>Human Pathology</i> , 2021, 112, 20-34.	1.1	19
28	Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127). <i>Endocrine Pathology</i> , 2017, 28, 253-268.	5.2	18
29	Defining clear cell papillary renal cell carcinoma in routine clinical practice. <i>Histopathology</i> , 2020, 76, 1093-1095.	1.6	17
30	Misidentification of <i>Neosartorya pseudofischeri</i> as <i>Aspergillus fumigatus</i> in a Lung Transplant Patient. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2722-2725.	1.8	16
31	Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase. <i>Endocrine Pathology</i> , 2017, 28, 269-275.	5.2	15
32	Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features. <i>Modern Pathology</i> , 2021, 34, 1935-1946.	2.9	15
33	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. <i>Journal of Clinical Pathology</i> , 2021, 74, 291-299.	1.0	14
34	RUNX2 (6p21.1) amplification in osteosarcoma. <i>Human Pathology</i> , 2019, 94, 23-28.	1.1	13
35	Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. <i>European Urology</i> , 2022, 81, 229-233.	0.9	12
36	Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 515-528.	1.2	12

#	ARTICLE	IF	CITATIONS
37	Renal Leiomyoma and Leiomyosarcoma. American Journal of Surgical Pathology, 2016, 40, 1557-1563.	2.1	11
38	Urinary Bladder Paragangliomas: Analysis of Succinate Dehydrogenase and Outcome. Endocrine Pathology, 2016, 27, 243-252.	5.2	11
39	Primary Female Urethral Carcinoma. American Journal of Surgical Pathology, 2020, 44, 1591-1601.	2.1	11
40	Secondary renal neoplasia following chemotherapy or radiation in pediatric patients. Human Pathology, 2020, 103, 1-13.	1.1	10
41	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 507-516.	2.0	10
42	Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20. Endocrine Pathology, 2018, 29, 236-241.	5.2	9
43	Assessment of <i>RAS</i> Dependency for <i>BRAF</i> Alterations Using Cancer Genomic Databases. JAMA Network Open, 2021, 4, e2035479.	2.8	9
44	Morphologic overlap between low-grade oncocytic tumor and eosinophilic variant of chromophobe renal cell carcinoma. Human Pathology, 2022, 119, 114-116.	1.1	9
45	Renal neoplasia with papillary architecture involving the pelvicalyceal system. Human Pathology, 2021, 107, 46-57.	1.1	7
46	Immunohistochemical expression of carbonic anhydrase 9, glucose transporter 1, and paired box 8 in von Hippel-Lindau disease-related lesions. Human Pathology, 2022, 123, 93-101.	1.1	7
47	Classification of <i>BRCA2</i> Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay. Clinical Cancer Research, 2022, 28, 3742-3751.	3.2	7
48	A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 512-524.	0.8	6
49	Renal Neoplasia in Cowden Syndrome. Mayo Clinic Proceedings, 2020, 95, 2808-2809.	1.4	5
50	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. Urology, 2020, 144, 111-116.	0.5	5
51	Juxtaglomerular Cell Tumor: A Rare, Curable Cause of Hypertension in a Young Patient. Urology, 2019, 134, 42-44.	0.5	4
52	Paratesticular Papillary Cystadenoma of the Epididymis in the Setting of von Hippel-Lindau. Mayo Clinic Proceedings, 2021, 96, 828-829.	1.4	4
53	TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas. Endocrine Pathology, 2022, 33, 304-314.	5.2	4
54	Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia. JAMA Network Open, 2021, 4, e2132615.	2.8	4

#	ARTICLE	IF	CITATIONS
55	TERT Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract. <i>European Urology Open Science</i> , 2022, 35, 74-78.	0.2	4
56	Paratesticular Adenomatoid Tumor. <i>Mayo Clinic Proceedings</i> , 2016, 91, e167-e168.	1.4	3
57	Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Mayo Clinic Proceedings</i> , 2020, 95, 619-621.	1.4	3
58	Renal Neoplasia in Hyperparathyroidism—Jaw Tumor Syndrome. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2730-2731.	1.4	3
59	A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. <i>Human Pathology</i> , 2019, 88, 48-59.	1.1	2
60	An update on the pathology of collecting duct & papillary renal cell carcinoma with a discussion of SNP-Arrays as an emerging laboratory technique. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, , .	0.8	2
61	Primary Renal Well-Differentiated Neuroendocrine Tumor (Carcinoid) in a Horseshoe Kidney. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1687-1688.	1.4	2
62	Re: Stanley Weng, Renzo G. DiNatale, Andrew Silagy, et al. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. <i>Eur Urol</i> 2021;79:468–77. <i>European Urology</i> , 2021, 80, e62-e63.	0.9	2
63	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. <i>Bladder Cancer</i> , 2021, 7, 1-6.	0.2	2
64	Cytogenetics of spermatocytic tumors with a discussion of gain of chromosome 12p in anaplastic variants. <i>Human Pathology</i> , 2022, 124, 85-95.	1.1	2
65	Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool. <i>Pathology Research and Practice</i> , 2022, 233, 153892.	1.0	2
66	Renin Production by Juxtaglomerular Cell Tumors and Clear Cell Renal Cell Carcinoma and the Role of Angiotensin Signaling Inhibitors. <i>Mayo Clinic Proceedings</i> , 2022, 97, 2050-2064.	1.4	2
67	Tuberous Sclerosis—Associated Renal Neoplasm. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1089-1090.	1.4	1
68	Fumarate Hydratase (FH) c.1431_1433dupAAA (p.Lys477dup) variant is not associated with FH protein deficiency and increased 2SC in two separate patients with renal neoplasia. <i>Human Mutation</i> , 2021, 42, 1362-1364.	1.1	1
69	Do We Have Sufficient Evidence to Define Prognosis for “Low-grade” Fumarate Hydratase “deficient Renal Cell Carcinoma?. <i>Advances in Anatomic Pathology</i> , 2022, 29, 178-181.	2.4	1
70	Renal Cell Carcinoma With Combined Loss of Fumarate Hydratase and SMARCB1/INI-1. <i>Mayo Clinic Proceedings</i> , 2022, 97, 630-632.	1.4	1
71	STAT6 Immunopositivity in Solitary Fibrous Tumor of Thyroid Gland. <i>Mayo Clinic Proceedings</i> , 2022, 97, 808-810.	1.4	1
72	Papillary Renal Cell Carcinoma With “Drop Metastasis” (Tumor Seeding) Involving the Distal Ureter. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1026-1028.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Postirradiation Angiosarcoma of the Urinary Bladder. Mayo Clinic Proceedings, 2022, 97, 1406-1408.	1.4	1
74	Young Female Patient With a Hepatic Adenoma: Determining Risk for Malignant Transformation. Mayo Clinic Proceedings, 2016, 91, e29-e30.	1.4	0
75	Diagnosing a Kidney Tumor. Mayo Clinic Proceedings, 2016, 91, e41-e42.	1.4	0
76	Pancreatic Tumor in a Patient With Parathyroid and Pituitary Disease. Mayo Clinic Proceedings, 2016, 91, e17-e18.	1.4	0
77	Testicular Seminoma. Mayo Clinic Proceedings, 2017, 92, e21-e22.	1.4	0
78	Papillary Urothelial Carcinoma. Mayo Clinic Proceedings, 2021, 96, 2746-2747.	1.4	0
79	Biphasic squamoid alveolar renal cell carcinoma: Cytologic features of a rare entity. Annals of Diagnostic Pathology, 2022, 58, 151906.	0.6	0
80	Reply to Yang Zhao, Wenda Wang, and Yushi Zhang's Letter to the Editor re: Sounak Gupta, Christine M. Lohse, Ross Rowsey, et al. Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberos Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. Eur Urol 2022;81:229-33. European Urology, 2022, , .	0.9	0